We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mechanism Boosts Effects of Cancer Treatments

By Biotechdaily staff writers
Posted on 06 Dec 2004
Scientists have found a new mechanism of pathway activation known to be involved in many cancers. More...
In addition, they discovered that when this mechanism is blocked, cells may become more sensitive to chemotherapeutic agents and radiation, thereby making them easier to kill.

Researchers from Mount Sinai School of Medicine (New York, NY, USA) studied the Wnt pathway, which is known to be essential to regulation of cell differentiation. Once differentiated, cell proliferation is restricted. When triggered, the Wnt pathway instructs cells not to differentiate, allowing them to grow uncontrollably, which can then lead to tumor development.

The Mount Sinai investigators found that in some ovarian, breast, and colon cancer cells this pathway becomes activated by the triggering of a receptor on the surface of the cell. The cell can stimulate itself, remain in an undifferentiated condition, and continue to grow unchecked. Also, they found that the pathway can be inactivated at the cell surface by compounds that block the receptor. When inactivated, these cancer cells become more sensitive to agents that induce cell death.

Whereas it has been known that the Wnt pathway is involved in nearly all cases of colon cancer and in some ovarian and skin cancers, this research was the first to implicate this pathway in breast cancer and to identify this mechanism in human tumor cells. The study was published in the November 2004 issue of Cancer Cell.

"An increasing number of cancer therapeutic agents are being developed to block pathways activated by interactions at the cell surface. This research provides a novel target to interfere with a pathway that is implicated in many cancer types,” remarked Dr. Stuart Aaronson, professor and chairman of oncologic sciences at Mount Sinai School of Medicine.

Dr. Anna Bafico, assistant professor of oncologic sciences at Mount Sinai concluded, "Selectively interfering in this pathway in cancer cells with this mechanism may make them more sensitive to existing treatments.”


New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.